A Bioequivalence study of a randomized, open-label, single dose, two-way crossover design with two-period, two-treatment, and two-sequence of Olmesartan Medoxomil tablets 40 mg relative to OLMETEC (TABLETS 40 MG) in healthy Thai volunteers under fasting condition

Start Date28 Apr 2025

Sponsor / Collaborator

Bio-innova Co., Ltd

NCT02493322

/ Not yet recruitingPhase 3

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan + Chlorthalidone, Produced by EMS S.A,in Arterial Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Start Date01 Dec 2024

Sponsor / Collaborator

EMS SA (Brazil)

NCT02483936

/ Not yet recruitingPhase 3

Efficacy and Safety Evaluation of the New Association on Fixed Dose of Olmesartan Medoxomil + Chlorthalidone (40mg + 12.5mg and 40mg + 25mg) Compared With BENICAR HCT® in Hypertension Control

The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the essential hypertension control.

Start Date01 Dec 2024

Sponsor / Collaborator

EMS SA (Brazil)

100 Clinical Results associated with Olmesartan Medoxomil

100 Translational Medicine associated with Olmesartan Medoxomil

100 Patents (Medical) associated with Olmesartan Medoxomil

2,546

Literatures (Medical) associated with Olmesartan Medoxomil

01 Apr 2026·DEN open

Olmesartan‐induced gastritis with no lower gastrointestinal symptoms: A case report

Article

Author: Kamiyama, Miki ; Ochi, Masahiro ; Kosaka, Satoshi

Abstract:

A 74‐year‐old man with decreased appetite, weight, and heartburn was referred to our hospital. His medications included olmesartan. Esophagogastroduodenoscopy (EGD) revealed antral‐dominant erosive gastritis and nodular mucosa. A gastric biopsy revealed inflammatory cell infiltration. The serum anti‐Helicobacter pylori immunoglobulin G antibody test result was negative. Famotidine was ineffective in relieving his symptoms, and esomeprazole failed to prevent overt gastric bleeding, which required endoscopic hemostasis. The working diagnosis was drug‐induced gastritis, particularly olmesartan‐induced gastritis. His appetite loss started to improve within a week of olmesartan withdrawal. The erosions healed on EGD 2 months later. Over the next 10 months, he remained in his usual state until olmesartan was inadvertently administered. Subsequent EGD revealed a mild gastritis relapse. We diagnosed olmesartan‐induced gastritis and discontinued olmesartan treatment. Mucosal healing was confirmed by EGD 1 year later. Olmesartan is known to cause angiotensin II receptor blocker‐induced enteropathy. Although angiotensin II receptor blocker‐induced enteropathy affects the stomach, angiotensin II receptor blocker‐induced gastritis without lower gastrointestinal symptoms is rare. The characteristic endoscopic appearance may provide a clue to the correct diagnosis.

01 Sep 2025·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Rapid quantification of 21 antihypertensive and diuretic drugs in plasma by UPLC-MS/MS: Application to clinical and forensic cases

Article

Author: Willeman, Théo ; Boudin, Coralie ; Scolan, Virginie ; Behouche, Alexandre ; Eysseric-Guérin, Hélène ; Stanke-Labesque, Françoise ; Ormezzano, Olivier ; Paysant, François ; Faure, Amandine

Systemic arterial hypertension, affecting more than 1 billion people worldwide, necessitates widespread use of antihypertensive and diuretic medications. However, the potential toxicity related to exposure of these medications is not always fully understood, potentially leading to underestimates of deaths related to cardiovascular drugs. Additionally, the growing interest in monitoring adherence to antihypertensive medications necessitates the development of specific analytical methods suitable for both clinical and forensic applications. In this study, we developed a novel, high-throughput quantitative method for the simultaneous analysis of 21 antihypertensive and diuretic drugs mainly in human plasma using liquid chromatography with tandem mass spectrometry. This method has several advantages, including minimal sample volume requirement, a one-step sample preparation using an Ostro® plate, and a chromatographic run time of 7 min. The method was successfully validated on 11 criteria following the European Medicines Agency's guidances. The method was successfully applied to authentic samples from 62 clinical cases and 76 post-mortem cases, with two cases of severe intoxications more precisely described. The first case describes an attempted suicide by candesartan (2558 ng/mL in plasma) combined with celiprolol (18 ng/mL) and amlodipine (161 ng/mL). The second case is a diuretic-contaminated dietary supplement poisoning with plasma concentrations of 40 ng/mL for furosemide and 36 ng/mL for hydrochlorothiazide. The authors present a simple, fast, and sensitive quantification method for the analysis of 21 antihypertensive and diuretic drugs, with concentration values reported in both living subjects and post-mortem cases to aid in the often-challenging interpretation of cardiotropic drug concentrations.

01 Sep 2025·ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

New insights into Baricitinib's immunomodulatory role in doxorubicin-induced cardiomyopathy: JAK/STAT and TLR-4/NF-κB pathways

Article

Author: El-Feky, Ola A ; Khedr, Eman G ; Badr, Noha H

Baricitinib recently gained attention as a selective Janus kinase inhibitor, mediating cytokine signaling pathways and immune-inflammatory cascades. This research designed to explore the potential cardioprotective impact of baricitinib in doxorubicin-induced cardiomyopathy (DIC), tracking its immunomodulatory effect on the JAK/STAT and TLR-4/NF-κB signaling pathways. We also compared its effect with olmesartan, an angiotensin receptor blocker (ARB), which is one of the treatments used for DIC. Five groups were created out of male albino rats: normal control group, doxorubicin group, baricitinib treatment group, olmesartan treatment group, combination treatment group. Doxorubicin, baricitinib and olmesartan were taken with dosages of 4.5 mg/kg day after day IP (Cumulative dose = 22.5 mg/kg), 3 mg/kg/day PO, 10 mg/kg/day PO, respectively for 10 days. The results showed that baricitinib exerted cardioprotective effect on histopathological and biochemical levels compared to doxorubicin group. It also downregulated the activation of the JAK/STAT signaling pathway via significant decreases in p-JAK2 and p-STAT1/3 compared to doxorubicin group. It also downregulated the TLR-4/NF-κB signaling pathway via significant decreases in TLR-4 and NF-κB compared to doxorubicin group. For the first time, we elucidated baricitinib's cardioprotective role against DIC thought modulation of the JAK/STAT and TLR-4/NF-κB immune-inflammatory pathways. Moreover, baricitinib significantly downregulated the two signaling pathways with subsequent downregulation of downstream markers; IL-6, TNF-α, VEGF-α, and NO, which are involved in inflammation and angiogenesis associated with DIC. Olmesartan alone or in combination with baricitinib also exerted cardioprotection by downregulating the two signaling pathways, while baricitinib demonstrated superior anti-inflammatory effects. Thus, baricitinib shows promise in mitigating DIC.

News (Medical) associated with Olmesartan Medoxomil

29 Aug 2025

·www.einpresswire.com

January - March 2021 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System (FAERS)

Addyi (flibanserin) Drug hypersensitivity The "Contraindications", "Warnings and Precautions", "Adverse Reactions", and "Medication Guide" sections of the labeling were updated in September 2021 to include hypersensitivity reactions. Addyi labeling Glucagon-like peptide-1 (GLP-1) analogues Adlyxin (lixisenatide) Bydureon (exenatide) Bydureon BCise (exenatide) Byetta (exenatide) Ozempic (semaglutide) Rybelsus (semaglutide) Saxenda (liraglutide) Soliqua (insulin glargine and lixisenatide) Trulicity (dulaglutide) Victoza (liraglutide) Xultophy (insulin degludec and liraglutide) Drug-induced liver injury The "Adverse Reactions" section of the liraglutide and dulaglutide labeling was updated in June 2022 to include information about elevations of liver enzymes. Example: Trulicity labeling FDA determined that no action is necessary at the time for lixisenatide, exenatide, and semaglutide based on available information. Alcohol-based hand sanitizers Exposure via inhalation FDA determined that no action is necessary at the time based on available information. A FDA Drug Safety Communication was issued on June 16, 2021. Amlodipine and Levamlodipine Products Azor (amlodipine and olmesartan medoxomil ) Caduet (amlodipine besylate and atorvastatin calcium) Conjupri (levamlodipine maleate) Consensi (amlodipine besylate and celecoxib) Exforge (amlodipine and valsartan) Exforge HCT (amlodipine/valsartan and hydrochlorothiazide) Lotrel (amlodipine besylate and benazepril hydrochloride) Katerzia (amlodipine benzoate) Norvasc (amlodipine besylate) Prestalia (amlodipine besylate and perindopril arginine) Tribenzor (amlodipine besylate/olmesartan medoxomil and hydrochlorothiazide) Twynsta (amlodipine and telmisartan) Non-cardiogenic pulmonary edema FDA determined that no action is necessary at the time based on available information. Avonex (interferon beta-1a) Betaseron (interferon beta-1b) Extavia (interferon beta-1b) Plegridy (pegylated interferon beta-1a) Rebif (interferon beta-1a) Injection site abscess FDA is evaluating the need for regulatory action. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Scleroderma FDA determined that no action is necessary at the time based on available information. Bavencio (avelumab) Imfinzi (durvalumab) Keytruda (pembrolizumab) Libtayo (cemiplimab-rwlc) Opdivo (nivolumab) Tecentriq (atezolizumab) Cholangitis sclerosing The "Adverse Reactions" section of the Keytruda (pembrolizumab) labeling was updated in August 2021 to include sclerosing cholangitis. Example: Keytruda labeling FDA determined that no action is necessary at the time for Bavencio (avelumab), Imfinzi (durvalumab), Libtayo (cemiplimab-rwlc), Opdivo (nivolumab), and Tecentriq (atezolizumab) based on available information. Chloroquine Generic products containing chloroquine Phospholipidosis The “Warnings” section of the labeling was updated in May 2022 to include information about phospholipidosis. Eliquis (apixaban) Pradaxa (dabigatran etexilate mesylate) Savaysa (edoxaban tosylate) Xarelto (ribaroxaban) Generic products containing dabigatran etexilate mesylate Generic products containing ribaroxaban Menorrhagia The “Use in Specific Populations” section was updated April 2021 to add language to describe the risk of clinically significant uterine bleeding in females of reproductive potential. Eliquis label Pradaxa label Savaysa label Xarelto label Depakote (divalproex sodium) Depakote ER (divalproex sodium) Stavzor (valproic acid) Generic products containing divalproex sodium Generic products containing valproic acid Tubulointerstitial nephritis The "Adverse Reactions" section of the labeling was updated in November 2021 to include tubulointerstitial nephritis. Example: Depakote labeling Dupixent (dupilumab) Alopecias FDA is evaluating the need for regulatory action. H.P. Acthar Gel (corticotropin) Anaphylactic and anaphylactoid responses The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include anaphylaxis. Acthar Gel labeling H.P. Acthar Gel (corticotropin) Cardiac arrhythmias The "Warnings and Precautions" and "Adverse Reactions" sections of the labeling were updated in October 2021 to include atrial fibrillations and palpitations. Acthar Gel labeling Ibrance (palbociclib) Kisqali (ribociclib) Kisqali Femara Co-Pack (letrozole and ribociclib) Verzenio (abemaciclib) Second primary malignancy FDA determined that no action is necessary at the time based on available information. Lynparza (olaparib) Drug-induced liver injury FDA determined that no action is necessary at the time based on available information. Ocrevus (ocrelizumab) Autoimmune colitis The "Warnings and Precautions", "Adverse Reactions", "Patient Counseling Information", and "Medication Guide" sections of the labeling were updated in August 2022 to include colitis. Ocrevus labeling Poteligeo (mogamulizumab-kpkc) Acute kidney injury The "Warnings and Precautions" section of the labeling was updated in March 2022 to include glomerulonephritis. Poteligeo labeling Ravicti (glycerol phenylbutyrate) Product labeling issue regarding stability and instructions for administration The container label, carton label, "Medication Guide", and sections of the Prescribing Information ("Dosage and Administration" and "Patient Counseling Information") were updated in September 2021 to enhance the instructions for administration. Ravicti labeling Spravato (esketamine) Hypertensive crisis FDA determined that no action is necessary at the time based on available information. Tremfya (guselkumab) Device use errors resulting in possible missed or partial doses The Tremfya One Press Instructions for Use (IFU) and carton labeling was updated in June 2023 to mitigate medication errors, such as underdose or no dose delivered. Tremfya labeling Trulance (plecanatide) Drug hypersensitivity The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include skin itching, hives, and rash. Trulance Label Trulance (plecanatide) Vomiting The “Adverse Reactions” section of the Trulance labeling was updated April 2021 to include vomiting. Trulance Label Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Drug Approval

15 Nov 2024

·www.businesswire.com

PCE Automation Acquires Olmec-UK

BECCLES, England--( BUSINESS WIRE )--Automation solutions provider, PCE Automation Ltd completes its second acquisition in just two years, with north Lincolnshire-based vision inspection and web conversion provider, Olmec-UK being the latest addition to its expanding portfolio. The acquisition was a strategic choice, allowing PCE Automation to strengthen its existing presence within the Life Science sector by bringing vision inspection and web conversion capabilities into its offering. PCE plans to diversify into new market segments within the medical device arena, such as Advanced Wound Care, Ostomy and Continence Care, Drug Delivery Systems, and Ocular. James Cook, CEO of PCE Automation said, “The acquisition of Olmec is a key milestone in delivering on our strategic business vision and goal of being a one-stop shop for medical clients. It will allow us to offer a full turnkey solution for our customers, helping to reduce complexity, time to market, friction costs, CapEx, and downtime throughout the full value chain.” The acquisition finalised in November 2024 following an 18-month process and is set to bring a 25% growth in sales orders, as well as providing PCE with a sales hub for the north of the UK. The north Lincolnshire location will be PCE’s fourth site, working alongside the existing sites in Beccles and Lutterworth, and the newly introduced Dublin site, following the acquisition of Adapt Engineering in 2023. The move also brings benefits to Olmec, from increased resources to full automation line capabilities. Robert Pounder, Managing Director of Olmec-UK said, “The two companies are very well aligned in terms of culture and delivering an excellent customer experience. In joining PCE Automation, we’re tapping into a wealth of resources and expertise that will help us to provide an enhanced experience for our customers. “Together with PCE, we look forward to delivering innovative, cutting-edge solutions that will make a real difference to Life Science manufacturing across PCE’s global automation footprint." About PCE Automation PCE Automation is a UK-based automation solutions provider with a global footprint. Specialising in the Life Science sector, PCE provides solutions for clients across the world. About Olmec-UK Olmec-UK is a vision inspection and web conversion company based in north Lincolnshire in the UK. Olmec has been serving a multitude of markets since 2006.

Acquisition

06 Nov 2024

·pharma.economictimes.indiatimes.com

Paracetamol to PAN-D: CDSCO finds over 50 sub-standard drugs. Check full list of medicines

New Delhi: The Central Drugs Standard Control Organisation ( CDSCO ) has identified over 50 drugs which have failed in the drug test. In its latest report, the controller said 50 drugs including Paracetamol are "not of standard quality" (NSQ). The report has also flagged calcium and vitamin D3 supplements, anti-diabetes pills, and high blood pressure medicines. Paracetamol tablets from Karnataka Antibiotics & Pharmaceuticals Ltd were specifically mentioned for quality concerns. The report listed a total of 48 drugs in the NSQ category, including a Gauze Roll Non Sterile Roller Bandage. NSQ alerts come from monthly random sampling conducted by state drug officers. Some of the medicines were produced by companies like Hetero Drugs, Alkem Laboratories, Hindustan Antibiotics Limited (HAL), Karnataka Antibiotics & Pharmaceuticals Ltd, Meg Lifesciences, and Pure & Cure Healthcare. Additionally, the CDSCO shared another list that features five more drugs that failed quality tests. The pharmaceutical companies denied responsibility for these drugs. They claim they are "spurious," and one response from a company stated, "The actual manufacturer (as per label claim) has informed that the impugned batch of the product has not been manufactured by them and that it is a spurious drug. The product is purported to be spurious; however, the same is subjected to outcome of investigation." CDSCO NSQ Test: Full list of drugs and their manufacturers Here is the list of drugs that failed the CDSCO test along with the manufacturers: Amoxicillin And Potassium Clavulanate Tablets IP (Clavam 625) - M/s. Alkem Health Science Amoxicillin & Potassium Clavulanate Tablets (Mexclav 625) - M/s. Meg Lifesciences Calcium And Vitamin D3 Tablets IP (Shelcal 500) - M/s. Pure & Cure Healthcare Pvt. Ltd. Metformin Hydrochloride Sustained-release Tablets IP (Glycimet-SR-500) - M/s. Scott-Edil Pharmacia Ltd. Vitamin B Complex with Vitamin C Softgels - M/s. Asoj Soft Caps Pvt. Ltd. Rifmin 550 (Rifaximin Tablets 550 mg) - M/s. Legen Healthcare Pantoprazole Gastro-Resistant and Domperidone Prolonged-Release Capsules IP (Pan - D) - M/s. Alkem Health Science Paracetamol Tablets IP 500 mg - M/s. Karnataka Antibiotics and Pharmaceuticals Ltd. Montair LC Kid (Montelukast Sodium & Levocetirizine Hydrochloride Dispersible Tablets) - M/s. Pure & Cure Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) (RL 500 ml) - M/s. Vision Parenteral Pvt. Ltd. Fexofenadine Hydrochloride Tablets IP 120 mg - M/s. Maxtar Bio-Genics Laxnorm Solution (Lactulose Solution USP) - M/s. Athens Life Sciences Heparin Sodium Injection 5000 Units (Hostranil Injection) - M/s. Health Biotech Ltd. Buflam Forte Suspension (Ibuprofen & Paracetamol Oral Suspension) - M/s. Ornate Pharma Pvt. Ltd. Cepodem XP 50 Dry Suspension (Cefpodoxime Proxetil and Potassium Clavulanate Oral Suspension) - M/s. Hetero Labs Limited Nimesulide, Paracetamol and Chlorzoxazone Tablets (NICIP MR) - M/s. HSN International Rolled Gauze (Non-Sterilized) - M/s. Blazon India Ciprofloxacin Tablets IP 500 mg (Ocif-500) - M/s. Ornate Labs Pvt. Ltd. Nimesulide, Phenylephrine Hydrochloride & Levocetirizine Dihydrochloride Tablets (Nunim-Cold) - M/s. Unispeed Pharmaceuticals Pvt. Ltd. Adrenaline Injection IP Sterile 1 ml - M/s. Alves Healthcare Pvt. Ltd. Compound Sodium Lactate Injection IP (Ringer Lactate Solution for Injection) RL 500ml - M/s. Vision Parentral Pvt. Ltd. Vingel XL Pro Gel (Diclofenac Diethylamine, Linseed Oil, Methyl Salicylate, and Menthol Gel) - M/s. Universal Twin Labs Atropine Sulphate Injection IP 2 ml - M/s. Nandani Medical Laboratories Pvt. Ltd. Cefoperazone & Sulbactam For Injection (Todaycef 1.5 G) - M/s. Daxin Pharmaceuticals Pvt. Ltd. Heparin Sodium Injection IP 25000 IU / 5ml - M/s. Scott-Edil Pharmacia Ltd. Cefepime & Tazobactam for Injection (Crupime - TZ Kid Injection) - M/s. Cosmas Research Lab. Ltd. Atropine Sulphate Injection IP (Atropine Sulphate) - M/s. Priya Pharmaceuticals Salbutamol, Bromhexine HCI, Guaifenesin and Menthol Syrup (Acozil Expectorant) - M/s. Antila Lifesciences Pvt. Ltd. Diclofenac Sodium IP - M/s. Sara Exports Ltd. Escitalopram and Clonazepam Tablets IP (Klozaps-ES Tablets) - M/s. Digital Vision Phenytoin Sodium Injection USP - M/s. Health Biotech Ltd. Paracetamol, Phenylephrine Hydrochloride and Cetirizine Hydrochloride Suspension (Cethel Cold DS Suspension) - M/s. Win Cure Pharma Calcium 500 mg with Vitamin D3 250 IU Tablets IP - M/s. Life Max Cancer Laboratories Amoxycillin and Potassium Clavulanate Tablets IP 625 mg (Renamega- CV 625) - M/s. Malik Lifesciences Pvt. Ltd. Olmesartan Medoxomil Tablets IP 40 mg - M/s. Life Max Cancer Laboratories INFUSION SET-NV - M/s. Medivision Healthcare Telmisartan Tablets IP 40 mg - M/s. Life Max Cancer Laboratories Alprazolam Tablets IP 0.25 mg (Erazol-0.25 Tablets) - M/s. Elikem Pharmaceuticals Pvt. Ltd. Glimepiride Tablets IP (2 mg) - M/s. Mascot Health Series Pvt. Ltd. Calcium and Vitamin D3 Tablets IP - M/s. Unicure India Ltd. Metronidazole Tablets IP 400mg - M/s. Hindustan Antibiotics Ltd. Paziva -40 - M/s. Gnosis Pharmaceuticals Pvt. Ltd. Pantomed -40 - Digital Vision 176 Cefixime Oral Suspension IP (Dry Syrup) - Nestor Pharmaceuticals Ltd. Moxymed CV - Alexa Pharmaceuticals Frusemide Injection IP 20 mg - Nestor Pharmaceuticals Ltd. Kudajarishtam - Bala Herbals Tab Nodosis - Steadfast Medishield Pvt. Ltd. Haridrakhanda - Bhaskara Vilasam Vaidyasala Pantoprazole Inj. BP 40 mg - Kerala Medical Services Corporation Ltd. Yogaraja Guggulu - Bhaskara Vilasam Vaidyasala PANCEF-OF - Aglomed Ltd.

Drug Approval

100 Deals associated with Olmesartan Medoxomil

External Link

KEGG	Wiki	ATC	Drug Bank
D01204	Olmesartan Medoxomil	C09CA08	DB00275

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertension	United States	Cosette Pharmaceuticals, Inc.	25 Apr 2002

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic Syndrome	Phase 3	Belgium	Daiichi Sankyo Europe GmbH	01 Aug 2008
Metabolic Syndrome	Phase 3	Germany	Daiichi Sankyo Europe GmbH	01 Aug 2008
Metabolic Syndrome	Phase 3	Italy	Daiichi Sankyo Europe GmbH	01 Aug 2008
Atrial Fibrillation	Phase 3	-	Daiichi Sankyo Co., Ltd.	01 Jan 2005
Diabetes Mellitus, Type 2	Phase 3	China	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Diabetes Mellitus, Type 2	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Diabetic Nephropathies	Phase 3	China	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Diabetic Nephropathies	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Kidney Failure, Chronic	Phase 3	China	Daiichi Sankyo Co., Ltd.	01 Apr 2003
Kidney Failure, Chronic	Phase 3	Japan	Daiichi Sankyo Co., Ltd.	01 Apr 2003

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05189015 (Pubmed \| Diabetol Metab Syndr)	Phase 4	Diabetes Mellitus, Type 2 \| Hypertension	80	Olmesartan 20 mg	ckerggotfw(wvczpftggf) = hkwlzvqzrc yamtlsflkm (jdzgqbnvna ) View more	-	11 Mar 2023
				Amlodipine 5 mg	ckerggotfw(wvczpftggf) = vevcdfrfgh yamtlsflkm (jdzgqbnvna ) View more
OCTOPUS (ERA2019)	Not Applicable	-	461	Olmesartan	mekrcubpap(ybyipbwetl) = vepyybmqvt cudcphnjhx (psvivfbiet )	Negative	13 Jun 2019
				Other antihypertensive medications	mekrcubpap(ybyipbwetl) = lgrzhfytnl cudcphnjhx (psvivfbiet )
NCT00417222 (SUPPORT, Pubmed \| Eur Heart J)	Phase 3	Chronic heart failure	1,147	Addition of olmesartan	kfkljepuei(invjfzpbps) = fzboionenk jhglmuwsrf (icmidoqoxt ) View more	Negative	14 Apr 2015
				olmesartan (Control)	izlhwpfzng(ukebszaxhc) = wcvagsmivb soolwaavqh (qvrfegazrz )
NCT00134160 (OSCAR, Pubmed \| Hypertens Res)	Phase 4	Hypertension	1,164	ARB	nvdjcwypkk(uhunzkgpso) = lzsfipyfgi oviqkspszk (igxxgjcfgr ) View more	-	01 Jun 2014
NCT00185159 (ROADMAP, ERA2014)	Phase 3	microalbuminuria	1,758	Olmesartan medoxomil (OM)	zmqhepxvsm(dwaqibpwrr) = bxvieijztm rxnaqtjrvn (fnmgnhuzpy ) View more	Positive	01 May 2014
				Placebo	zmqhepxvsm(dwaqibpwrr) = etfdjsasoz rxnaqtjrvn (fnmgnhuzpy ) View more
NCT00185159 (ROADMAP, Pubmed \| J Am Heart Assoc)	Phase 3	Diabetes Mellitus	4,449	Olmesartan medoxomil (OM)	exdmufjiik(srlrxeadmu) = luqrtgvlcz eomwhchowe (rdyxetlzqx ) View more	Positive	01 Jan 2014
				Placebo	exdmufjiik(srlrxeadmu) = jfgogbfnea eomwhchowe (rdyxetlzqx ) View more
NCT00151814 (Pubmed \| Paediatr Drugs)	Phase 1	Hypertension	24	olmesartan medoxomil (Group 2)	xiyzzsmfcn(chgctwwrmb) = cnggubjtsu bydtsifufh (vczxqpcsxy ) View more	-	01 Dec 2012
				olmesartan medoxomil (Group 3)	xiyzzsmfcn(chgctwwrmb) = lnycopxafd bydtsifufh (vczxqpcsxy ) View more
NCT00649389 (TRINITY, Pubmed)	Phase 3	Cardiovascular Diseases \| Diabetes Mellitus \| Hypertension ... View more	2,500	Olmesartan 40 mg/Amlodipine besylate 10 mg/Hydrochlorothiazide 25 mg	rdsbutatpz(twjtwfwshg) = jfglxnhsns exzuvefcrt (jlcsoqlxha ) View more	-	30 Oct 2012
				Olmesartan 40 mg/Amlodipine besylate 10 mg	rdsbutatpz(twjtwfwshg) = ldsnoypeda exzuvefcrt (jlcsoqlxha ) View more
NCT00949884 (Pubmed \| Adv Ther)	Phase 4	Hypertension	941	Olmesartan Medoxomil	pkljjmdlno(xhzjhpqnpg) = knndmkzxrh unyzpwovrz (bteabvlctk ) View more	-	01 Jun 2012
				Losartan Potassium	pkljjmdlno(xhzjhpqnpg) = cuxfhtcsvf unyzpwovrz (bteabvlctk ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis